<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0002020'>Gastroesophageal reflux disease</z:hpo> and <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> (BE) are associated with increased risk of esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>However, the majority of patients with <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> have no <z:hpo ids='HP_0002020'>gastroesophageal reflux disease</z:hpo> symptoms, and few patients with <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> have BE at the time of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> diagnosis </plain></SENT>
<SENT sid="2" pm="."><plain>Furthermore, the annual incidence of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> in individuals with BE appears to be low </plain></SENT>
<SENT sid="3" pm="."><plain>The utility of screening for BE in <z:hpo ids='HP_0002020'>gastroesophageal reflux disease</z:hpo> patients and of routine endoscopic monitoring in BE patients remain unclear </plain></SENT>
<SENT sid="4" pm="."><plain>More prospective data on disease progression and an improved knowledge of risk factors are needed to help define optimal management strategies </plain></SENT>
</text></document>